The pharmacokinetics of anthocyanins and their metabolites in humans.
The pharmacokinetics of anthocyanins and their metabolites in humans.
复制标题
DOI:
10.1111/bph.12676
复制
发表时间:
2014-07
影响因子:
7.3
通讯作者:
Kay CD
中科院分区:
文献类型:
--
作者:
de Ferrars RM;Czank C;Zhang Q;Botting NP;Kroon PA;Cassidy A;Kay CD
Anthocyanins are phytochemicals with reported vasoactive bioactivity. However, given their instability at neutral pH, they are presumed to undergo significant degradation and subsequent biotransformation. The aim of the present study was to establish the pharmacokinetics of the metabolites of cyanidin-3-glucoside (C3G), a widely consumed dietary phytochemical with potential cardioprotective properties. A 500 mg oral bolus dose of 6,8,10,3′,5′-13C5-C3G was fed to eight healthy male participants, followed by a 48 h collection (0, 0.5, 1, 2, 4, 6, 24, 48 h) of blood, urine and faecal samples. Samples were analysed by HPLC-ESI-MS/MS with elimination kinetics established using non-compartmental pharmacokinetic modelling. Seventeen 13C-labelled compounds were identified in the serum, including 13C5-C3G, its degradation products, protocatechuic acid (PCA) and phloroglucinaldehyde (PGA), 13 metabolites of PCA and 1 metabolite derived from PGA. The maximal concentrations of the phenolic metabolites (Cmax) ranged from 10 to 2000 nM, between 2 and 30 h (tmax) post-consumption, with half-lives of elimination observed between 0.5 and 96 h. The major phenolic metabolites identified were hippuric acid and ferulic acid, which peaked in the serum at approximately 16 and 8 h respectively. Anthocyanins are metabolized to a structurally diverse range of metabolites that exhibit dynamic kinetic profiles. Understanding the elimination kinetics of these metabolites is key to the design of future studies examining their utility in dietary interventions or as therapeutics for disease risk reduction.
登录
查看更多内容
影响因子:
6.1
作者:
Nizamutdinova, Irina Tsoy;Kim, Young Min;Kim, Hye Jung
通讯作者:
Kim, Hye Jung
影响因子:
5.2
作者:
de Ferrars, Rachel M.;Cassidy, Aedin;Kay, Colin D.
通讯作者:
Kay, Colin D.
影响因子:
5.2
作者:
Kay, Colin D.;Kroon, Paul A.;Cassidy, Aedin
通讯作者:
Cassidy, Aedin
影响因子:
37.8
作者:
Cassidy A;Mukamal KJ;Liu L;Franz M;Eliassen AH;Rimm EB
通讯作者:
Rimm EB
DOI:
10.1186/1472-6904-5-2
发表时间:
2005-03-03
期刊:
BMC clinical pharmacology
影响因子:
--
作者:
Anupongsanugool E;Teekachunhatean S;Rojanasthien N;Pongsatha S;Sangdee C
通讯作者:
Sangdee C